Aralez Pharmaceuticals Q2 2016 Earnings Corporate Overview

Q2 2016 earnings presentation covering portfolio commercialization of YOSPRALA and Fibricor, financial results, and near-term business priorities. Discusses YOSPRALA FDA approval timeline, launch strategy for 4Q 2016, and business development framework focused on profitability by 2018.